Woojung Lee is an experienced professional specializing in health economics and decision modeling. As the Associate Director at the Institute for Clinical and Economic Review since May 2024, Woojung Lee brings a wealth of expertise from previous roles, including Associate at Analysis Group, where contributions involved economic evaluations and health technology assessment strategies for pharmaceutical stakeholders. At Curta, leadership in a significant analysis of administrative claims data demonstrated the value of Botox treatment timing. Time spent at the University of Washington fostered research skills in machine learning applications and real-world evidence in economic assessments. Academic credentials include a PhD in Comparative Health Outcomes, Policy, and Economics from the University of Washington and a PharmD from Seoul National University.
This person is not in any teams
Institute for Clinical and Economic Review (ICER)
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including prescription drugs, other treatments, and diagnostic tests. In collaboration with patients, clinical experts, and other key stakeholders, ICER analyzes the available evidence on the benefits and risks of these interventions to measure their value and suggest fair prices. ICER also regularly reports on the barriers to care for patients and recommends solutions to ensure fair access to prescription drugs. For more information about ICER, please visit www.icer.org.